Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Webinar: Using machine learning to identify adverse events from scientific literature

Posted on February 5th, 2020 by

The “vigilance” aspect of the pharmacovigilance process can be very challenging. Always being on guard and knowing all of the places to look can be difficult. In a sea of information, it can even seem like a nearly impossible task to maintain awareness of all adverse events (AE). That is why there has been a lot of buzz around technologies that can help automate parts of the pharmacovigilance process.

(more…)

Why literature is a valuable source for signal detection: From the EU point of view

Posted on January 9th, 2020 by

Signal detection is traditionally based on case reporting from healthcare professionals and national regulatory authorities. Yet, there are a number of very notable examples where a safety signal actually came from the scientific literature, such as in the cases of thalidomide, GM-CSF, nifedipine and tamsulosin. (You can learn more about how safety signals detected from a literature report had an impact on the lifecycle of these drugs here.)

(more…)

Evidence-based medicine training and seminar coming up in Beijing

Posted on January 3rd, 2020 by

Systematic review of the available literature from clinical trials is important for collecting evidence for existing and new patient care practices. With the ever-increasing amount of literature around this, it becomes important to design literature searches that ensure no important safety signal is missed.

(more…)

PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator

Posted on December 11th, 2019 by

medicine

When taking a new drug, most patients’ chief concern is whether or not that drug is going to have the intended effect. They aren’t always thinking about what other drugs they might already be taking, and how those drugs could be affected by the new one.

(more…)

  1. 1
  2. 2
  3. 3
  4. …
  5. 17